Delving into the Latest Updates on Testosterone with Synapse

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

Start Date01 Jun 2025

Sponsor / Collaborator

Transdermal Delivery Solutions Corp.

NCT06733350 / Not yet recruitingPhase 4IIT

Investigating the Effect of Testosterone Replacement Therapy Among Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the patient's condition through regular physical exams and blood tests, but not giving treatment unless there are changes in test results. It can be a practical alternative to treatment in localized prostate cancer. Hypogonadal men have low testosterone associated with symptoms such as low libido and erectile problems. TRT can be used to treat hypogonadism by increasing testosterone levels, which may improve associated symptoms. TRT is often not used in men with prostate cancer due to concerns it may lead to the cancer growing or spreading. This may lead hypogonadal men to have a poor quality of life or to discontinue AS. TRT may improve treatment and quality of life outcomes in hypogonadal men with localized prostate cancer on active surveillance.

Start Date01 Jan 2025

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

RBR-8xtsgvv / Not yet recruitingNot ApplicableIIT

Evaluation of Metabolic, Inflammatory, Cardiovascular and Endothelial Risk markers in transgender men on Testosterone therapy

Start Date15 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Testosterone

Login to view more data

100 Translational Medicine associated with Testosterone

Login to view more data

100 Patents (Medical) associated with Testosterone

Login to view more data

61,693

Literatures (Medical) associated with Testosterone

01 May 2025·Journal of Environmental Sciences

The effects of 17β-trenbolone and bisphenol A on sexual behavior and social dominance via the hypothalamic-pituitary-gonadal axis in male mice

Article

Author: Sun, Minghe ; Luan, Jialu ; Zhao, Qili ; Zhang, Shuhui ; Bai, Huijuan ; Feng, Xizeng ; Sun, Mingzhu ; Zhao, Xin ; Yu, Qian ; Fu, Zhenhua ; Zuo, Xiang

17β-Trenbolone (17-TB) is well documented as an environmental endocrine disruptor in aquatic biological studies, but its effects on mammals remain poorly understood. Furthermore, 17-TB acts as a hormone with properties similar to testosterone, and the consequences of juvenile exposure on adult social behavior remain uncertain. Bisphenol A (BPA) acts as an estrogen-like hormone, compared to 17-TB. Three-week-old male Balb/c mice were exposed orally to 17-TB (100 µg/(kg·day)) and BPA (4 mg/(kg·day)) for 28 days. Assessments of social interactions and a three-chamber test showed that 17-TB increased virility in male mice, intensified both male and female sexual behavior, and attracted and accepted female mice. It also increased social dominance through tube tests in male mice and markedly activated the c-Fos⁺ immune response in the medial prefrontal cortex (mPFC) and basal amygdala (BLA). ELISA data showed that 17-TB and BPA exposure significantly affected serum gonadotropin-releasing hormone (GnRH), growth hormone (GH), estradiol (E2), and luteinizing hormone (LH) levels, as well as testicular lesions and androgen receptor (ARβ) and estrogen receptor (ERα) synthesis. Testicular transcriptomic analysis further confirmed that could disrupt steroid synthesis and linoleic acid-related biometabolic processes. These findings suggest the influence of 17-TB and BPA exposure on sexual behavior and fertility in male mice, possibly through modulation of the hypothalamic-pituitary-gonadal axis. This study provides insights relevant to human reproductive health and neuro-social behavioral research, and the potential risk of environmental disturbances should not be overlooked.

01 Mar 2025·Journal of Orthopaedics

Geographical incidence of testosterone supplementation in total hip and knee arthroplasty

Article

Author: Kuznetsov, Mikhail ; Smith, Eric L ; Grant, Andrew ; Coden, Gloria ; Smith, Eric L.

Introduction:

Prescription testosterone usage in the United States declined after 2013 following reports of its association with myocardial infarction and stroke. However, more recently there has been a documented increase in testosterone prescriptions. Recently, testosterone levels have also been hypothesized to increase infection risk in patients undergoing elective shoulder arthroplasty. Furthermore, testosterone may increase the risk of venous thromboembolism. These complications are perioperative concerns for total hip and knee arthroplasties (THA/TKA). Therefore, the purpose of our study is to identify trends in the incidence of testosterone prescriptions in patients who underwent THA/TKA with respect to geographical population data.

Methods:

We retrospectively reviewed 40,711 primary THAs and 50,893 primary TKAs performed in males between 1/1/2016 and 12/31/2021 using a commercial claims database. Records were reviewed for demographics, geographical location, and supplemental testosterone prescriptions within 1 year prior to surgery. Patient Metropolitan Statistical Area (MSA) was assessed with respect to United States Census Population Data.

Results:

We identified 91,604 males who underwent primary THA (n = 40,711) or TKA (n = 50,893). For THA/TKA, patients who were younger had a higher likelihood of having a supplemental testosterone prescription (OR = 0.99, 95 % CI [0.99-1.00], p < 0.001). TKA patients (2,507, 4.9 %) had a higher rate of testosterone prescriptions than THA patients overall (1,413, 3.4 %), (OR = 1.44 95 % CI [1.35, 1.54], p < 0.001) as well as within each year.For THA and TKA patients, patients in the Midwest (OR = 1.61, p < 0.001), South (OR = 3.04, p < 0.001), and West (OR = 2.28, p < 0.001) regions all had higher testosterone prescription rates than the Northeast. Patients living in a city (MSA population ≥200,000) were more likely to be prescribed testosterone (OR = 1.20, p = 0.002).

Conclusion:

Surgeons conducting TKA/THA should be aware that younger patients, those in higher population areas, and those in the Midwest, South, and West regions are more likely to be prescribed testosterone than those in the Northeast.

01 Feb 2025·NEUROCHEMICAL RESEARCH

Lactobacillus Helveticus Improves Controlled Cortical Impact Injury-Generated Neurological Aberrations by Remodeling of Gut-Brain Axis Mediators

Article

Author: Pasam, Tulasi ; Dandekar, Manoj P. ; Dandekar, Manoj P ; Padhy, Hara Prasad

Considerable studies augured the potential of gut microbiota-based interventions in brain injury-associated complications. Based on our earlier study results, we envisaged the sex-specific neuroprotective effect of Lactobacillus helveticus by remodeling of gut-brain axis. In this study, we investigated the effect of L. helveticus on neurological complications in a mouse model of controlled cortical impact (CCI). Adult, male and female, C57BL/6 mice underwent CCI surgery and received L. helveticus treatment for six weeks. Sensorimotor function was evaluated via neurological severity score and rotarod test. Long-term effects on anxiety-like behavior and cognition were assessed using the elevated-zero maze (EZM) and novel object recognition test (NORT). Brain perilesional area, blood, colon, and fecal samples were collected post-CCI for molecular biology analysis. CCI-operated mice displayed significant neurological impairments at 1-, 3-, 5-, and 7-days post-injury (dpi) and exhibited altered behavior in EZM and NORT compared to sham-operated mice. However, these behavioral changes were ameliorated in mice receiving L. helveticus. GFAP, Iba-1, TNF-α, and IL-1β expressions and corticotrophin-releasing hormone (CRH) levels were elevated in the perilesional cortex of CCI-operated male/female mice. These elevated biomarkers and decreased BDNF levels in both male/female mice were modified by L. helveticus treatment. Additionally, L. helveticus treatment restored altered short-chain fatty acids (SCFAs) levels in fecal samples and improved intestinal integrity but did not affect decreased plasma levels of progesterone and testosterone in CCI mice. These results indicate that L. helveticus exerts beneficial effects in the CCI mouse model by mitigating inflammation and remodeling of gut microbiota-brain mediators.

201

News (Medical) associated with Testosterone

12 Dec 2024

·www.prnewswire.com

AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII

WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. "Azurity's purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients." Testosterone cypionate intramuscular injections are commonly used as a testosterone replacement therapy for patients with low testosterone by drawing up testosterone cypionate doses from a vial, then administering with a syringe. Azmiro provides an FDA-approved prefilled option now available as a 200 mg/mL single dose syringe. Safety and efficacy of Azmiro in men with age-related hypogonadism have not been established. For full Azmiro prescribing information, including medication guide, please go to azmiro.com. About Azurity Pharmaceuticals, Inc. Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. We supply a large number of products to treat a wide range of medical conditions. These include anti-infective, cardiovascular/cardiology, central nervous system/cerebrovascular, endocrinology, gastrointestinal, immunology, and oncology medicines. Many of our medicines are dose-form innovations for patients with needs that are not met by other available products. Our medicines have benefited millions of people. For more information, visit . PP-AZO-US-0033 SOURCE Azurity Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

03 Dec 2024

·www.globenewswire.com

KYZATREX® (testosterone undecanoate) CIII Capsules EXPANDS DISTRIBUTION THROUGH NEW COLLABORATION WITH GAMEDAY MEN’S HEALTH

The Deal Gives Gameday Men’s Health Patients Access to The FDA-Approved Oral Testosterone Therapy At 250+ Health Centers RALEIGH, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Gameday Men’s Health, the leader in men’s health clinics nationwide, today announced it is expanding its testosterone therapy options to include KYZATREX® (testosterone undecanoate) CIII capsules. Partnering with Marius Pharmaceuticals, Gameday Men’s Health now provides access to FDA-approved KYZATREX, a prescription medication for adult men who have low or no testosterone due to certain medical conditions, in all Gameday Men’s Health centers across 48 states. KYZATREX is available in an oral form, providing a non-invasive and convenient alternative to traditional injection-based methods. Gameday Men’s Health is a pioneering health clinic designed to help men reclaim their lives by optimizing four common areas of male concern - low testosterone, erectile dysfunction and enhancement, weight loss, and vitamin therapy. With in-house labs, expert medical teams, and personalized treatment plans, Gameday delivers discreet, effective solutions to support men’s optimal health and vitality. Shalin Shah, CEO of Marius Pharmaceuticals, says, “Given the staggering numbers of testosterone deficient men across the country, we are glad to see KYZATREX offered at one of the most rapidly growing men’s clinics. It is critical that we normalize this critical, metabolic therapy so men feel comfortable getting the care that they need and glad to see Gameday solving this issue.” The launch of KYZATREX at Gameday Men’s Health comes at a time when testosterone deficiency is a rising global epidemic as it affects approximately four in 10 men older than 45 years and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society (2022). Testosterone deficiency is bi-directional with metabolic diseases and early research indicates a role in further conditions such as depression and inflammatory diseases. While TRT has traditionally consisted of injections, implanted pellets, patches, or gels, KYZATREX instead delivers testosterone through a twice-daily, softgel capsule that is safe and convenient. The oral delivery excludes the administration pain, mess, transference risk to others around you, and changes to eating habits which can occur with other TRT delivery systems. KYZATREX is primarily absorbed via the lymphatic system, effectively bypassing the liver and avoiding toxicity. “Our goal has always been to make men's health accessible and adaptable. Oral TRT provides men with a choice in TRT that aligns with their preferences, allowing them to feel their best with minimal interruption to their daily lives,” said Evan Miller, CEO and Founder of Gameday Men’s Health. For more information about Gameday Men’s Health visit gamedaymenshealth.com. For more information about KYZATREX, visit www.kyzatrex.com, and for more information about Marius Pharmaceuticals, visit www.mariuspharma.com. About Marius Pharmaceuticals Marius Pharmaceuticals strives to better the lives of patients by focusing on therapies designed for hypogonadism or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system. For more information, please visit www.mariuspharma.com. About Gameday Men’s HealthGameday Men's Health is a premier men’s health clinic offering a range of services, including testosterone replacement therapy, erectile dysfunction treatment, weight loss programs, and vitamin therapy. Founded in 2018, this franchise is designed to help men transform their lives with a simple, three-step signature process: testing, proprietary wellness plans, and personalized treatment sessions. For more information, please visit www.gamedaymenshealth.com About KYZATREX® (testosterone undecanoate)KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) and indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males between 18 and 65 years of age with documented hypogonadism, as defined by a below normal serum testosterone level (≤281 ng/dL) and at least one sign or symptom of testosterone deficiency. In the efficacy population (n=139), 88 percent of hypogonadal men treated with KYZATREX achieved a mean plasma total testosterone concentration (Cavg) over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic (PK) visit of the study at Day 90 (primary endpoint). Based on exploratory endpoints, patients who received KYZATREX reported improvements in symptoms of low testosterone, including quality of life, energy/fatigue, erectile function, sexual intercourse, and mood. The most common side effect reported in ≥2 percent of KYZATREX patients was increased blood pressure (2.6%). The safety and efficacy of KYZATREX in males less than 18 years old have not been established. Please see additional Important Safety Information for KYZATREX below, including Boxed Warning for potential increased blood pressure, or visit www.kyzatrex.com.Important Safety Information for KYZATREX® (Testosterone Undecanoate Capsules)UseKYZATREX® (testosterone undecanoate) is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions. KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in children. KYZATREX is not meant for use by women. Important Safety Information for KYZATREX® KYZATREX can increase blood pressure, which can increase the risk of having a heart attack or stroke and can increase risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke. If your blood pressure increases while on KYZATREX, blood pressure medicines may need to be started. If you are currently taking blood pressure medicines, they may need to be changed or new blood pressure medicines may need to be added to control your blood pressure.If your blood pressure cannot be controlled, KYZATREX may need to be stopped.Your healthcare provider will monitor your blood pressure while you are being treated with KYZATREX. Do not take KYZATREX if you: have breast cancer; have or might have prostate cancer; are a woman who is pregnant (KYZATREX may harm your unborn baby); are allergic to KYZATREX or any of its ingredients; or have low testosterone without certain medical conditions (e.g., do not take KYZATREX if you have low testosterone due to age). Before you take KYZATREX, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure or are treated for high blood pressure; have a history of diabetes; have heart problems; have high red blood cell count (hematocrit) or high hemoglobin laboratory value; have urinary problems due to an enlarged prostate; have liver or kidney problems; or have problems breathing while you sleep (sleep apnea). Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking KYZATREX with certain other medicines can affect each other. Especially, tell your healthcare provider if you take: insulin; medicines that decrease blood clotting (blood thinners); corticosteroids; or medicines that increase blood pressure, such as some cold medicine and pain medicines. KYZATREX may cause other serious side effects including: Increase in red blood cell count (hematocrit) or hemoglobin, which can increase the risk of blood clots, strokes, and heart attacks. You may need to stop KYZATREX if your red blood cell count increases.If you already have an enlarged prostate, your signs and symptoms may worsen while taking KYZATREX. These may include: increased urination at night; trouble starting your urine stream; urinating many times during the day; urge to go to the bathroom right away; a urine accident; inability to pass urine or weak urine flow.Increased risk of prostate cancer.Blood clots in the legs or lungs. Signs and symptoms of a blood clot in your leg can include pain, swelling or redness. Signs and symptoms of a blood clot in your lungs can include difficulty breathing or chest pain.Abuse. Testosterone can be abused when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Abuse can cause serious heart and psychological side effects.In large doses, KYZATREX may lower your sperm count.Liver problems. Symptoms of liver problems may include: nausea or vomiting; yellowing of your skin or whites of your eyes; dark urine; pain on the right side of your stomach area (abdominal pain).Swelling of your ankles, feet, or body (edema), with or without heart failure.Enlarged or painful breasts.Breathing problems while you sleep (sleep apnea). Call your healthcare provider right away if you have any of the serious side effects listed above. The most common side effect of KYZATREX is high blood pressure. Other side effects may include: headache, joint or back pain, diarrhea, increased red blood cell count, anxiety, constipation, swelling of the legs, and increased prostate specific antigen (PSA) levels. These are not all the possible side effects of KYZATREX. For more information, ask your healthcare provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Marius [by visiting www.mariuspharma.com]. Keep KYZATREX and all medicines out of the reach of children. See Full Prescribing Information and Medication Guide for KYZATREX. Media Contact:Marius PharmaceuticalsLilly Washburn lilly@mariuspharma.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3da5b291-b193-4057-9ec7-7e72839cddd9

Clinical ResultPhase 3Drug Approval

27 Nov 2024

·www.prnewswire.com

Halozyme to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follows: A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Testosterone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00075	Testosterone	G03BA03	DB00624

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
secondary testicular failure	US	Endo Operations Ltd.	29 Dec 2010
Sexual Dysfunctions, Psychological	EU	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	EU	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	IS	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	IS	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	LI	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	LI	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	NO	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	NO	Warner Chilcott Ltd.	28 Jul 2006
Low testosterone levels	US	Endo Operations Ltd.	31 Oct 2002
Testosterone deficiency	AU	Teva Pharmaceuticals Australia Pty Ltd	10 Apr 2002
Hypogonadism	US	AbbVie, Inc.	29 Sep 1995

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Klinefelter Syndrome	Phase 3	US	Amneal Intermediate, Inc.	01 Mar 2014
Arthralgia	Phase 3	US	National Cancer Institute	01 Aug 2013
Arthralgia	Phase 3	PR	National Cancer Institute	01 Aug 2013
Breast Cancer	Phase 3	US	National Cancer Institute	01 Aug 2013
Breast Cancer	Phase 3	PR	National Cancer Institute	01 Aug 2013
Hot Flashes	Phase 3	US	National Cancer Institute	01 Aug 2013
Hot Flashes	Phase 3	PR	National Cancer Institute	01 Aug 2013
Musculoskeletal Abnormalities	Phase 3	US	National Cancer Institute	01 Aug 2013
Musculoskeletal Abnormalities	Phase 3	PR	National Cancer Institute	01 Aug 2013
Alzheimer Disease	Phase 3	US	Solvay Pharmaceuticals, Inc.	01 Jul 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW	Not Applicable	Primary Malignant Liver Neoplasm testosterone \| estradiol \| tumor necrosis factor receptor superfamily member 9 (TNFRS9) ... View more	-	TESTOSTERONE (Estradiol levels)	qppqspvjos(heloirlgiu) = fdggphjoao favpoktdck (cdrbtmgmgs ) View more	Positive	13 Oct 2024
SFN2024	Not Applicable	-	-	Testosterone-treated female X. laevis	bywkoljijo(tadoozcjva) = the quantity of PNNs in testosterone-treated, fully masculinized female brains was similar to those of sham-operated female brains uowaehthzw (eopjyiyobc )	-	07 Oct 2024
				testosterone (Sham-operated female X. laevis)
NCT05781685 (CTgov)	Early Phase 1	Acute Pain	20	Testosterone+Placebo Syrup (Testosterone)	tpzkyfnfng(zlgdpcjjhd) = zwbwsvfulm ogfmlcqyvd (dpoxfgrlcf, jzjeewnnfo - jalelodvxa) View more	-	05 Aug 2024
				Testosterone+Placebo Syrup (Placebo)	tpzkyfnfng(zlgdpcjjhd) = teoiogqqun ogfmlcqyvd (dpoxfgrlcf, aifkielrzg - nwwuemkzec) View more
ADA2024	Not Applicable	Obesity	-	Testosterone Replacement Therapy (TRT)	nkeildtfkh(wzeacfmjmg) = bpmzczqutg jueifpkylt (ggijiwftgr ) View more	-	14 Jun 2024
ATS2024	Not Applicable	Acute Lung Injury	-	Anabolic Testosterone Isocaproate	cwbciewqui(ndzsvyelyo) = Our patient is a 46-year-old smoker who presented with two days of progressively dyspnea preceded by two weeks of cough. His history was significant for polysubstance use disorder. In the emergency department, he was found to be hypoxic to 60% with diffuse crackles and expiratory wheezes on exam, so he was given a dose of systemic steroids and started nebulizers. Chest radiograph and chest CT scan (figure 1) showed diffuse bilateral ground glass opacities. His respiratory status deteriorated rapidly, and he was intubated, then he was ultimately admitted to the MICU for acute hypoxemic respiratory failure. All infectious work-up including sputum culture and rapid respiratory pathogen PCR were negative. Over the next three days, he continued to have higher oxygen requirements, so empiric steroids were given then flexible bronchoscopy was performed with BAL demonstrating eosinophils of 14%, and lymphocytes of 3%. BAL bacterial and fungal cultures were negative. He was started on IV methylprednisolone, responded very well and after 3 days he was extubated. Following extubation, he reported using non-prescribed anabolic testosterone isocaproate for bodybuilding over the past several months and had three similar presentations with respiratory distress with chest CT also showing bilateral ground glass opacities and negative infectious workup. In all of them, he exhibited clinical improvement following each of these presentations with normal chest radiographs in between. He was followed in pulmonary clinic and was advised to stop using anabolic steroids with no recurrence to date. ptxqmlstur (ernqvtwmni )	-	19 May 2024
ISN WCN2024	Not Applicable	Infarction	-	Rivaroxaban 15mg/day	mcxyejwnot(gvcnwaikjz) = zcwracjdqg uhulwfnhds (ksuyhiupnt )	-	01 Apr 2024
NCT03518034 (TRAVERSE, CTgov)	Phase 4	Hypogonadism \| Cardiovascular Diseases	5,246	AndroGel® (AndroGel 1.62%)	algcghoswp(vunxyqmcfm) = tfjvysdbpo uofshhigrg (rqlkbwjrmt, abzjndzucb - egxhgakluy) View more	-	13 Mar 2024
				Placebo (Placebo)	algcghoswp(vunxyqmcfm) = ggscmwptql uofshhigrg (rqlkbwjrmt, mvgvrunvza - crmnqwheog) View more
NCT00467987 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2 \| secondary testicular failure \| Atherosclerosis ... View more	47	androgel (Androgel)	jpccvbtalj(suntvvipup) = pxihwpbjkr iepjuvjuvd (ctqomikugb, ctcyoueofb - kkultdjlmn) View more	-	06 Feb 2024
				placebo (Placebo)	jpccvbtalj(suntvvipup) = wodmbqplnm iepjuvjuvd (ctqomikugb, exssyzjxpr - grfhueantz) View more
NCT03518034 (TRAVERSE, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 4	Hypogonadism	5,204	Testosterone gel	jyblhoanst(lsxpuukrdi) = ederzmswex rirmjthgfg (ijqkyywhat )	Negative	18 Jan 2024
				Placebo gel	jyblhoanst(lsxpuukrdi) = wbgswqtdut rirmjthgfg (ijqkyywhat )
NCT04439799 (CTgov)	Phase 4	Eunuchism	81	Testosterone Cypionate 200 Mg/ML (Testosterone Cypionate Group)	ajljbqyyaf(epdncracaa) = gldnrsjftd lynlhpzfzy (wicdkmxsyp, vpgkmgezxi - bryqwumntn) View more	-	13 Dec 2023
				Intranasal Testosterone (Natesto Group)	ajljbqyyaf(epdncracaa) = crhxwcztfx lynlhpzfzy (wicdkmxsyp, lxhqabuzyx - jcgyjntpcy) View more